Skip to main
TVGN
TVGN logo

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings Inc. possesses a robust competitive edge due to its innovative platform technology, which not only targets infectious diseases but also shows potential in treating solid tumors and autoimmune diseases, thereby significantly expanding its addressable market. The company's TVGN 489 treatment stands out as it allows cancer patients with SARS-CoV-2 to maintain ongoing oncologic care, reducing the risk of treatment interruptions often caused by viral infections. Furthermore, Tevogen's impressive capability to move from discovery to clinical applications in just 18 months demonstrates its operational efficiency and commitment to advancing cutting-edge medical solutions.

Bears say

Tevogen Bio Holdings faces significant challenges in the effectiveness of traditional antiviral strategies, which may hinder the success of its immunotherapy treatments, particularly for cancer patients undergoing delays in their therapy. The company's reliance on targets that remain preserved during the pandemic contrasts with the vulnerabilities of existing vaccines and monoclonal antibodies that may quickly lose efficacy due to mutations. Additionally, the potential negative outcomes associated with treatment delays for critical patient populations further undermine confidence in Tevogen’s therapeutic prospects and overall market position.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.